source
- Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pendingPharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval dec…Fierce Biotech · 8h ago↗ source
- Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpointA pivotal trial of Bristol Myers Squibb’s GPRC5D-directed CAR-T cell therapy has hit its primary endpoint, furthering the drugmaker’s efforts to challenge Johnson & Johnson for the post-BCMA multip…Fierce Biotech · 8h ago↗ source
- Boston Scientific recalls spinal cord implant in wake of more than 1k serious injuriesBoston Scientific has issued another recall, this time for its spinal cord implant used to treat pain.